NCT07004647View on ClinicalTrials.gov

MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

November 30, 2028

Conditions
Peritoneal Tumor
Interventions
DRUG

Fludarabine

D-10 to D-2: Fludarabine (25 mg/m2/day) will be administered intravenously for 3 days;D-10 to D-2: Cyclophosphamide (250 mg/m2/day) will be administered intravenously for 3 days.

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER